Citius Oncology, Inc.: Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse ...

Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

Blood lactate levels can predict physical outcomes for ALS patients

Higher levels of blood lactate may be the key to a longer life for people with the neurodegenerative condition ALS, new ...
Gut

Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
Investing

Quantify 2X Daily Alt Season Crypto ETF (QXAS)

Tidal Trust II - Quantify 2x Daily Alt Season Crypto ETF is an exchange traded fund launched and managed by Tidal Investments LLC. The fund is co-managed by Quantify Chaos Advisors, LLC. The fund ...
Seeking Alpha

CPRA Calamos Russell 2000 Strctrd Alt Prot ETF - Apr

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...